A drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors.
| Member | Definition | Class |
|---|
| 2-thiosalicylic acid | A sulfanylbenzoic acid that is the 2-sulfanyl derivative of benzoic acid. | thiosalicylic acid |
| 3-hydroxyacetanilide | A derivative of phenol which has an acetamido substituent located meta to the phenolic -OH group. It is a non-toxic regioisomer of paracetamol with analgesic properties, but has never been marketed as a drug. | metacetamol |
| 4-(5-(4-fluorophenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl)benzenesulfonamide | A member of the class of pyrazoles that is 1H-pyrazole which is substituted at positions 1, 3 and 5 by 4-sulfamoylphenyl, trifluoromethyl and 4-fluorophenyl groups, respectively. A selective cyclooxygenase 2 inhibitor, it is used in veterinary medicine to treat pain and inflammation in dogs with degenerative joint disease. | mavacoxib |
| aceclofenac | A monocarboxylic acid that is the carboxymethyl ester of diclofenac. A non-steroidal anti-inflammatory drug related to diclofenac, it is used in the management of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. | aceclofenac |
| acemetacin | A carboxylic ester that is the carboxymethyl ester of indometacin. A non-steroidal anti-inflammatory drug, it is used in the treatment of rheumatoid arthritis, osteoarthritis, and low back pain, as well as for postoperative pain and inflammation. Its activity is due to both acemetacin and its major metabolite, indometacin. | acemetacin |
| acetaminophen | A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group. | paracetamol |
| acetosyringone | A member of the class of acetophenones that is 1-phenylethanone substituted by a hydroxy group at position 4 and methoxy groups at positions 3 and 5. | acetosyringone |
| acetovanillone | An aromatic ketone that is 1-phenylethanone substituted by a hydroxy group at position 4 and a methoxy group at position 3. | apocynin |
| alclofenac | An aromatic ether in which the ether oxygen links an allyl group to the 4-position of (3-chlorophenyl)acetic acid.A non-steroidal anti-inflammatory drug, it was withdrawn from the UK market in 1979 due to concerns with its association with vasculitis and rash. | alclofenac |
| alminoprofen | A substituted aniline that is ibuprofen in which the isobutyl group is replaced by a (2-methylprop-2-en-1-yl)amino group. A non-steroidal anti-inflammatory drug, it is used for treatment of inflammatory and rheumatic disorders. | alminoprofen |
| amantadine | A member of the class of adamantanes that is used as an antiviral and antiparkinson drug. | amantadine |
| amfenac | An oxo monocarboxylic acid that is benzophenone in which one of the phenyl groups is substituted by an amino group and a carboxymethyl group at position 2 and 3, respectively. The corresponding carboxamide, nepafenac, is a prodrug of amfenac and is used for the treatment of pain and inflammation following cataract surgery. | amfenac |
| aminopyrine | A pyrazolone that is 1,2-dihydro-3H-pyrazol-3-one substituted by a dimethylamino group at position 4, methyl groups at positions 1 and 5 and a phenyl group at position 2. It exhibits analgesic, anti-inflammatory, and antipyretic properties. | aminophenazone |
| ampyrone | A pyrazolone, a member of the class of pyrazoles that is antipyrine substituted at C-4 by an amino group. It is a metabolite of aminopyrine and of metamizole. | 4-aminoantipyrine |
| antipyrine | A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2. | antipyrine |
| aspirin | A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity. | acetylsalicylic acid |
| benoxaprofen | A monocarboxylic acid that is propionic acid substituted at position 2 by a 2-(4-chlorophenyl)-1,3-benzoxazol-5-yl group. It was used as a non-steroidal anti-inflammatory drug until 1982 when it was withdrawn from the market due to adverse side-effects including liver necrosis, photosensitivity, and carcinogenicity in animals. | benoxaprofen |
| bromfenac | Amfenac in which the the hydrogen at the 4 position of the benzoyl group is substituted by bromine. It is used for the management of ocular pain and treatment of postoperative inflammation in patients who have undergone cataract extraction. It was withdrawn from the US market in 1998, following concerns over off-label abuse and hepatic failure. | bromfenac |
| bufexamac | A hydroxamic acid derived from phenylacetamide in which the benzene moiety is substituted at C-4 by a butoxy group. It has anti-inflammatory, analgesic, and antipyretic properties. | bufexamac |
| capsaicin | | capsaicin |
| carbachol | | carbachol |
| carbamazepine | A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant. | carbamazepine |
| celecoxib | A member of the class of pyrazoles that is 1H-pyrazole which is substituted at positions 1, 3 and 5 by 4-sulfamoylphenyl, trifluoromethyl and p-tolyl groups, respectively. A cyclooxygenase-2 inhibitor, it is used in the treatment of arthritis. | celecoxib |
| clonixin | A pyridinemonocarboxylic acid that is nicotinic acid substituted at position 2 by a (2-methyl-3-chlorophenyl)amino group. Used (as its lysine salt) for treatment of renal colic, muscular pain and moderately severe migraine attacks. | clonixin |
| deracoxib | A member of the class of pyrazoles that is 1H-pyrazole which is substituted at positions 1, 3, and 5 by 4-sulfamoylphenyl, difluoromethyl and 3-fluoro-4-methoxyphenyl groups, respectively. A selective cyclooxygenase 2 inhibitor, it is used in veterinary medicine for the control of pain and inflammation associated with osteoarthritis in dogs. | deracoxib |
| dexibuprofen | | dexibuprofen |
| dexketoprofen | A monocarboxylic acid that is (S)-hydratropic acid substituted at position 3 on the phenyl ring by a benzoyl group. A cyclooxygenase inhibitor, it is used to relieve short-term pain, such as muscular pain, dental pain and dysmenorrhoea. | dexketoprofen |
| dexmedetomidine | | dexmedetomidine |
| diclofenac | A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position. | diclofenac |
| difenpiramide | A monocarboxylic acid amide obtained by formal condensation of the carboxy group from biphenyl-4-ylacetic acid with the amino group of 2-aminopyridine. Used for treatment of rheumatoid arthritis. | difenpiramide |
| diflunisal | An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position. | diflunisal |
| dihydroergotamine | Ergotamine in which a single bond replaces the double bond between positions 9 and 10. A semisynthetic ergot alkaloid with weaker oxytocic and vasoconstrictor properties than ergotamine, it is used (as the methanesulfonic or tartaric acid salts) for the treatment of migraine and orthostatic hypotension. | dihydroergotamine |
| dihydroergotamine mesylate | The methanesulfonic acid salt of dihydroergotamine, a semisynthetic ergot alkaloid with weaker oxytocic and vasoconstrictor properties than ergotamine. Both the mesylate and the tartrate salts are used for the treatment of migraine and orthostatic hypotension. | dihydroergotamine mesylate |
| dimethyl sulfoxide | A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents. | dimethyl sulfoxide |
| dipyrone | A pyrazole that is antiipyrine substituted at C-4 by a methyl(sulfomethyl)amino group, the sodium salt of which, metamizole sodium, was widely used as a powerful analgesic and antipyretic, but withdrawn from many markets from the 1970s due to a risk of causing risk of causing agranulocytosis. | metamizole |
| dipyrone | An organic sodium salt of antipyrine substituted at C-4 by a methyl(sulfonatomethyl)amino group, commonly used as a powerful analgesic and antipyretic. | metamizole sodium |
| dronabinol | A diterpenoid that is 6a,7,8,10a-tetrahydro-6H-benzo[c]chromene substituted at position 1 by a hydroxy group, positions 6, 6 and 9 by methyl groups and at position 3 by a pentyl group. The principal psychoactive constituent of the cannabis plant, it is used for treatment of anorexia associated with AIDS as well as nausea and vomiting associated with cancer chemotherapy. | Delta(9)-tetrahydrocannabinol |
| droxicam | An organic heterotricyclic compound that is 2H,5H-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-dioxide substituted at positions 3 and 5 by pyridin-2-yl and methyl groups respectively. A prodrug of piroxicam, it is used for the relief of pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis. | droxicam |
| ergotamine | A peptide ergot alkaloid that is dihydroergotamine in which a double bond replaces the single bond between positions 9 and 10. | ergotamine |
| etodolac | A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active. | etodolac |
| fendosal | A benzoindole that is 4,5-dihydro-3H-benzo[e]indole in which the nitrogen is substituted by a 3-carboxy-4-hydroxyphenyl group. A non-narcotic analgesic and non-steroidal anti-inflammatory drug, it has greater analgesic and inflammatory responses than aspirin but with less gastrointestinal toxicity. | fendosal |
| fenoprofen | A monocarboxylic acid that is propanoic acid in which one of the hydrogens at position 2 is substituted by a 3-phenoxyphenyl group. A non-steroidal anti-inflammatory drug, the dihydrate form of the calcium salt is used for the management of mild to moderate pain and for the relief of pain and inflammation associated with disorders such as arthritis. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding. | fenoprofen |
| fenoprofen calcium | The dihydrate form of the calcium salt of fenoprofen. A non-steroidal anti-inflammatory drug, it is used for the management of mild to moderate pain and for the relief of pain and inflammation associated with disorders such as arthritis. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding. | fenoprofen calcium |
| firocoxib | An enol ether that is the cyclopropylmethyl ether of 3-hydroxy-5,5-dimethyl-4-[4-(methylsulfonyl)phenyl]furan-2-one. A selective cyclooxygenase 2 inhibitor, it is used in veterinary medicine for the control of pain and inflammation associated with osteoarthritis in horses and dogs. | firocoxib |
| flufenamic acid | An aromatic amino acid consisting of anthranilic acid carrying an N-(trifluoromethyl)phenyl substituent. An analgesic and anti-inflammatory, it is used in rheumatic disorders. | flufenamic acid |
| flunixin | A pyridinemonocarboxylic acid that is nicotinic acid substituted at position 2 by a 2-methyl-3-(trifluoromethyl)phenylamino group. A relatively potent non-narcotic, nonsteroidal analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic properties; used in veterinary medicine (usually as the meglumine salt) for treatment of horses, cattle and pigs. | flunixin |
| flunixin meglumine | An organoammonium salt obtained by combining flunixin with one molar equivalent of 1-deoxy-1-(methylamino)-D-glucitol. A relatively potent non-narcotic, nonsteroidal analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic properties; used in veterinary medicine for treatment of horses, cattle and pigs. | flunixin meglumine |
| flurbiprofen | A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain. | flurbiprofen |
| friedelin | A pentacyclic triterpenoid that is perhydropicene which is substituted by an oxo group at position 3 and by methyl groups at the 4, 4a, 6b, 8a, 11, 11, 12b, and 14a-positions (the 4R,4aS,6aS,6bR,8aR,12aR,12bS,14aS,14bS-enantiomer). It is the major triterpenoid constituent of cork. | friedelin |
| glafenine | A carboxylic ester that is 2,3-dihydroxypropyl anthranilate in which the amino group is substituted by a 7-chloroquinolin-4-yl group. A non-steroidal anti-inflammatory drug, glafenine and its hydrochloride salt were used for the relief of all types of pain, but high incidence of anaphylactic reactions resulted in their withdrawal from the market. | glafenine |
| ibufenac | A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 4-isobutylphenyl group. Although it was shown to be effective in treatment of rheumatoid arthritis, the clinical use of ibufenac was discontinued due to hepatotoxic side-effects. | ibufenac |
| ibuprofen | A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-(2-methylpropyl)phenyl group. | ibuprofen |
| ibuproxam | A hydroxamic acid obtained by formal condensation of the carboxy group of ibuprofen with the amino group of hydroxylamine. Used for treatment of pain and inflammation associated with musculoskeletal and joint disorders. | ibuproxam |
| indoprofen | A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-(1-oxo-1,3-dihydroisoindol-2-yl)phenyl group. Initially used as an anti-inflammatory and analgesic, it was withdrawn from the market due to causing severe gastrointestinal bleeding. It has been subsequently found to increase production of the survival motor neuron protein. | indoprofen |
| kebuzone | A pyrazolidine that is phenylbutazone in which the two methylene hydrogens at postion 3 on the butyl chain are replaced by an oxo group. | kebuzone |
| lamotrigine | A member of the class of 1,2,4-triazines in which the triazene skeleton is substituted by amino groups at positions 3 and 5, and by a 2,3-dichlorophenyl group at position 6. | lamotrigine |
| lonazolac | A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 3-(4-chlorophenyl)-1-phenylpyrazol-4-yl group. | lonazolac |
| lornoxicam | A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 6-chloro-4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain, primarily resulting from inflammatory diseases of the joints, osteoarthritis, surgery, sciatica and other inflammations. | lornoxicam |
| loxoprofen | A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-[(2-oxocyclopentyl)methyl]phenyl group. A prodrug that is rapidly converted into its active trans-alcohol metabolite following oral administration. | loxoprofen |
| lysine clonixinate | An organoammonium salt obtained by combining clonixin with one molar equivalent of L-lysine. Used for treatment of renal colic, muscular pain and moderately severe migraine attacks. | clonixin lysine salt |
| methotrimeprazine | A member of the class of phenothiazines that is 10H-phenothiazine substituted by a (2R)-3-(dimethylamino)-2-methylpropyl group and a methoxy group at positions 10 and 2 respectively. | methotrimeprazine |
| methoxyflurane | An ether in which the two groups attached to the central oxygen atom are methyl and 2,2-dichloro-1,1-difluoroethyl. | methoxyflurane |
| miroprofen | A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-(imidazo[1,2-a]pyridin-2-yl)phenyl group. A non-steroidal anti-inflammatory drug that also exhibits analgesic, antipyretic and platelet aggregation inhibition properties. | miroprofen |
| mobiflex | A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis. It is also indicated for short term treatment of acute musculoskeletal disorders including strains, sprains and other soft-tissue injuries. | tenoxicam |
| mofebutazone | A pyrazolidine that is phenylbutazone lacking one of the phenyl substituents. It is used for treatment of joint and muscular pain. | mofebutazone |
| nabumetone | A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs. | nabumetone |
| naproxen | A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes. | naproxen |
| naproxen sodium | An organic sodium salt consisting of equimolar amounts of naproxen(1-) anions and sodium anions. | naproxen sodium |
| naproxen-n-butyl nitrate | A carboxylic ester obtained by formal condensation of the carboxy group of naproxen with the hydroxy group of 4-(nitrooxy)butanol. A cyclooxygenase-inhibiting nitric oxide donator that is metabolised to naproxen and a nitric oxide donating moiety, effective in treatment of osteoarthritis. | naproxcinod |
| naproxol | An aromatic ether in which the substituents on oxygen are 6-[(2S)-1-hydroxypropan-2-yl]-2-naphthyl and methyl. | naproxol |
| nepafenac | A monocarboxylic acid amide that is amfenac in which the carboxylic acid group has been converted into the corresponding carboxamide. It is a prodrug for amfenac, used in eye drops to treat pain and inflammation following cataract surgery. | nepafenac |
| noramidopyrine | A member of the class of pyrazoles that is antipyrine substituted at C-4 by a methylamino group. It is a metabolite of aminopyrine and of metamizole. | 4-(methylamino)antipyrine |
| oxamethacin | A hydroxamic acid obtained by formal condensation of the carboxy group of indometacin with the amino group of hydroxylamine. | oxametacin |
| oxyphenbutazone | A metabolite of phenylbutazone obtained by hydroxylation at position 4 of one of the phenyl rings. Commonly used (as its hydrate) to treat pain, swelling and stiffness associated with arthritis and gout, it was withdrawn from the market 1984 following association with blood dyscrasis and Stevens-Johnson syndrome. | oxyphenbutazone |
| parecoxib | An N-acylsulfonamide resulting from the formal condensation of valdecoxib with propionic acid. It is a prodrug for valdecoxib. | parecoxib |
| parthenolide | A sesquiterpene lactone and active principle of Feverfew (Tanacetum parthenium). | parthenolide |
| phenacetin | A member of the class of acetamides that is acetamide in which one of the hydrogens attached to the nitrogen is substituted by a 4-ethoxyphenyl group. | phenacetin |
| phenazopyridine | A diaminopyridine that is 2,6-diaminopyridine substituted at position 3 by a phenylazo group. A local anesthetic that has topical analgesic effect on mucosa lining of the urinary tract. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity. | phenazopyridine |
| phenazopyridine hydrochloride | A hydrochloride obtained by combining phenazopyridine with one equivalent of hydrochloric acid. A local anesthetic that has topical analgesic effect on mucosa lining of the urinary tract. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity. | phenazopyridine hydrochloride |
| phenylbutazone | A member of the class of pyrazolidines that is 1,2-diphenylpyrazolidine-3,5-dione carrying a butyl group at the 4-position. | phenylbutazone |
| pirfenidone | A pyridone that is 2-pyridone substituted at positions 1 and 5 by phenyl and methyl groups respectively. An anti-inflammatory drug used for the treatment of idiopathic pulmonary fibrosis. | pirfenidone |
| proglumetacin | A carboxylic ester obtained by formal condensation of the carboxy group of indometacin with the hydroxy group of 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl N(2)-benzoyl-N,N-dipropyl-alpha-glutaminate. Used (as its dimaleate salt) to control pain and inflammation associated with musculoskeletal and joint disorders. Following oral administration, it is metabolised to indometacin and proglumide, a drug with antisecretory effects that helps prevent injury to the stomach lining. | proglumetacin |
| propyphenazone | A pyrazolone derivative that is antipyrine substituted at C-4 by an isopropyl group. | propyphenazone |
| quinine | A cinchona alkaloid that is cinchonidine in which the hydrogen at the 6-position of the quinoline ring is substituted by methoxy. | quinine |
| robenacoxib | An aromatic amino acid that is 2-amino-5-ethylphenylacetic acid in which one of the amino hydrogens is replaced by a 2,3,5,6-tetrafluorophenyl group. A selective cyclooxygenase 2 inhibitor that is used in veterinary medicine for the relief of pain and inflammation in cats and dogs. | robenacoxib |
| salicin | An aryl beta-D-glucoside that is salicyl alcohol in which the phenolic hydrogen has been replaced by a beta-D-glucosyl residue. | salicin |
| salicylamide | The simplest member of the class of salicylamides derived from salicylic acid. | salicylamide |
| salicylsalicylic acid | A dimeric benzoate ester obtained by intermolecular condensation between the carboxy of one molecule of salicylic acid with the phenol group of a second. It is a prodrug for salycylic acid that is used for treatment of rheumatoid arthritis and osteoarthritis and also shows activity against type II diabetes. | salsalate |
| sodium bromfenac | The sesquihydrate of the sodium salt of bromfenac. It is used for the management of ocular pain and treatment of postoperative inflammation in patients who have undergone cataract extraction. | bromfenac sodium salt sesquihydrate |
| sulindac | A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions. | sulindac |
| suprofen | An aromatic ketone that is thiophene substituted at C-2 by a 4-(1-carboxyethyl)benzoyl group. | suprofen |
| suxibuzone | A pyrazolidine that is phenylbutazone which is substituted by a 3-carboxypropanoylmethyl group at the 4-position. Suxibuzone is a prodrug for phenylbutazone and is commonly used as an anti-inflammatory drug in horses. | suxibuzone |
| tepoxalin | A hydroxamic acid obtained by formal condensation of the carboxy group of 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]propanoic acid with the amino group of N-methylhydroxylamine. It is used in veterinary medicine for the control of pain and inflammation caused by musculoskeletal disorders such as hip dysplasia and arthritis in dogs. | tepoxalin |
| tetrahydropalmatine | A berberine alkaloid obtained by formal addition of two molecules of hydrogen to the pyridine ring of palmatine. | tetrahydropalmatine |
| tofisopam | An organic sodium salt having loxoprofen(1-) as the counterion. The parent acid, loxoprofen, is a prodrug that is rapidly converted to its active trans-alcohol metabolite following oral administration. | loxoprofen sodium |
| tolfenamic acid | An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 3-chloro-2-methylphenyl group. Tolfenamic acid is used specifically for relieving the pain of migraine. It also shows anticancer activity. | tolfenamic acid |
| ulixacaltamide | | ulixacaltamide |
| valdecoxib | A member of the class of isoxazoles that is isoxazole which is substituted at positions 3, 4 and 5 by phenyl, p-sulfamoylphenyl and methyl groups, respectively. A selective cyclooxygenase 2-inhibitor, it used as a nonsteroidal anti-inflammatory drug (NSAID) for the treatment of arthritis from 2001 until 2005, when it was withdrawn following concerns of an associated increased risk of heart attack and stroke. | valdecoxib |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 27.3783 | 1 | 16 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 23.4732 | 1 | 6 |
| 67.9K protein | Vaccinia virus | Potency | 15.8898 | 2 | 13 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 42.9544 | 4 | 17 |
| acid sphingomyelinase | Homo sapiens (human) | Potency | 7.0795 | 1 | 1 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 21.3898 | 2 | 11 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 26.6630 | 1 | 25 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 25.1189 | 1 | 1 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 28.1838 | 1 | 1 |
| AR protein | Homo sapiens (human) | Potency | 24.8765 | 12 | 139 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 22.3409 | 3 | 31 |
| arylsulfatase A | Homo sapiens (human) | Potency | 9.1368 | 1 | 5 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 19.6799 | 3 | 13 |
| Ataxin-2 | Homo sapiens (human) | Potency | 23.4283 | 1 | 9 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 0.9883 | 2 | 9 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 17.7605 | 2 | 14 |
| atrial natriuretic peptide receptor 1 precursor | Homo sapiens (human) | Potency | 0.1510 | 1 | 1 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 11.1783 | 2 | 16 |
| BRCA1 | Homo sapiens (human) | Potency | 11.2947 | 1 | 2 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 50.3404 | 1 | 3 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 34.6501 | 1 | 7 |
| caspase-3 | Cricetulus griseus (Chinese hamster) | Potency | 35.2796 | 1 | 3 |
| caspase-3 | Homo sapiens (human) | Potency | 34.6501 | 1 | 7 |
| Caspase-7 | Cricetulus griseus (Chinese hamster) | Potency | 35.2796 | 1 | 3 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 37.6153 | 3 | 34 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 18.0732 | 2 | 6 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 25.3397 | 1 | 22 |
| Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 31.6228 | 1 | 1 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 18.7279 | 2 | 8 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 27.7716 | 1 | 5 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 22.2258 | 1 | 8 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 27.9456 | 2 | 12 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 53.1764 | 1 | 2 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 1.5384 | 1 | 14 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 18.2907 | 1 | 8 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 13.5006 | 1 | 10 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 27.9456 | 2 | 12 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 74.3195 | 2 | 30 |
| ClpP | Bacillus subtilis | Potency | 31.6228 | 1 | 1 |
| cytochrome P450 2C19 precursor | Homo sapiens (human) | Potency | 8.5988 | 1 | 6 |
| cytochrome P450 2C9 precursor | Homo sapiens (human) | Potency | 17.0511 | 1 | 12 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 16.8362 | 1 | 22 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 20.8735 | 1 | 14 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 9.6330 | 1 | 3 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 15.5346 | 2 | 38 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 16.8360 | 2 | 19 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 27.6584 | 1 | 19 |
| D(1A) dopamine receptor | Homo sapiens (human) | Potency | 2.5975 | 2 | 4 |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Potency | 5.4077 | 1 | 6 |
| DNA dC->dU-editing enzyme APOBEC-3F isoform a | Homo sapiens (human) | Potency | 35.4813 | 1 | 1 |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | Potency | 3.1623 | 1 | 1 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 89.1251 | 1 | 1 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 52.6766 | 1 | 8 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 23.6305 | 1 | 3 |
| dopamine D1 receptor | Homo sapiens (human) | Potency | 0.0820 | 1 | 1 |
| endonuclease IV | Escherichia coli | Potency | 9.0170 | 1 | 2 |
| Endothelin receptor type B | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1 | 1 |
| Endothelin-1 receptor | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1 | 1 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 19.7139 | 12 | 174 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 28.0651 | 3 | 30 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 33.1925 | 9 | 129 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 14.4679 | 1 | 30 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 17.8360 | 4 | 39 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 28.5568 | 4 | 19 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 20.5222 | 1 | 2 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 11.3180 | 1 | 2 |
| G | Vesicular stomatitis virus | Potency | 16.8362 | 1 | 22 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 15.5346 | 1 | 19 |
| GALC protein | Homo sapiens (human) | Potency | 0.7079 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 15.5346 | 1 | 19 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 15.5346 | 1 | 19 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 15.5346 | 1 | 19 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 15.5346 | 1 | 19 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 15.5346 | 1 | 19 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 15.5346 | 1 | 19 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 15.5346 | 1 | 19 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 15.5346 | 1 | 19 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 15.5346 | 1 | 19 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 15.5346 | 1 | 19 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 15.5346 | 1 | 19 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 15.5346 | 1 | 19 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 15.5346 | 1 | 19 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 15.5346 | 1 | 19 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 15.5346 | 1 | 19 |
| geminin | Homo sapiens (human) | Potency | 8.5599 | 2 | 42 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 18.7228 | 3 | 49 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 17.6780 | 2 | 7 |
| GLS protein | Homo sapiens (human) | Potency | 23.1368 | 2 | 21 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 10.8455 | 1 | 5 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 20.4075 | 5 | 44 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 31.6884 | 1 | 14 |
| Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 16.9036 | 1 | 2 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 13.5546 | 1 | 2 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 12.5893 | 1 | 1 |
| heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) | Homo sapiens (human) | Potency | 23.9111 | 1 | 5 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 27.9321 | 2 | 11 |
| hemoglobin subunit beta | Homo sapiens (human) | Potency | 16.0599 | 3 | 4 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 17.1853 | 2 | 46 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 21.2995 | 1 | 7 |
| histone deacetylase 9 isoform 3 | Homo sapiens (human) | Potency | 27.1750 | 2 | 19 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 62.0274 | 2 | 10 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 41.4904 | 1 | 2 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 16.8362 | 1 | 22 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 6.6943 | 2 | 3 |
| hypothetical protein, conserved | Trypanosoma brucei | Potency | 32.1220 | 1 | 2 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 40.1715 | 2 | 11 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 6.8097 | 2 | 18 |
| IDH1 | Homo sapiens (human) | Potency | 11.9810 | 1 | 12 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 51.0004 | 2 | 3 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 16.8362 | 1 | 44 |
| Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 3.9152 | 1 | 2 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 12.9244 | 1 | 2 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 12.9244 | 1 | 2 |
| Interferon beta | Homo sapiens (human) | Potency | 19.1575 | 3 | 37 |
| interleukin 8 | Homo sapiens (human) | Potency | 86.8781 | 1 | 3 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 7.2915 | 1 | 24 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 17.3926 | 1 | 2 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 21.8119 | 4 | 37 |
| luciferase | Photuris pensylvanica (Pennsylania firefly) | Potency | 14.1254 | 1 | 1 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 0.5889 | 2 | 4 |
| M-phase phosphoprotein 8 | Homo sapiens (human) | Potency | 44.6684 | 1 | 2 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 24.1484 | 2 | 19 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 19.9962 | 2 | 9 |
| muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 2.3753 | 1 | 2 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 38.3687 | 1 | 8 |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 0.5889 | 1 | 2 |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 0.5889 | 1 | 2 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 8.0826 | 1 | 2 |
| NFKB1 protein, partial | Homo sapiens (human) | Potency | 9.3871 | 2 | 6 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 9.5194 | 1 | 7 |
| NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 1.4538 | 1 | 2 |
| Nrf2 | Homo sapiens (human) | Potency | 10.9498 | 2 | 3 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 33.2081 | 4 | 50 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 24.6396 | 1 | 9 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 31.8539 | 2 | 11 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 30.3071 | 1 | 6 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 16.4856 | 2 | 21 |
| nuclear receptor subfamily 1, group I, member 2 | Rattus norvegicus (Norway rat) | Potency | 7.7126 | 1 | 3 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 29.6095 | 3 | 53 |
| P53 | Homo sapiens (human) | Potency | 30.0594 | 1 | 2 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 33.6069 | 1 | 5 |
| Parkin | Homo sapiens (human) | Potency | 20.5962 | 1 | 1 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 14.5383 | 2 | 16 |
| peripheral myelin protein 22 isoform 1 | Homo sapiens (human) | Potency | 84.9214 | 1 | 4 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 27.0813 | 5 | 44 |
| Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) | Potency | 28.1838 | 1 | 1 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 22.8685 | 5 | 24 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 61.2584 | 2 | 10 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 3.6053 | 1 | 5 |
| polyprotein | Zika virus | Potency | 11.3180 | 1 | 2 |
| polyunsaturated fatty acid lipoxygenase ALOX12 | Homo sapiens (human) | Potency | 12.5893 | 1 | 1 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 17.6684 | 1 | 5 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 26.7228 | 1 | 6 |
| PPM1D protein | Homo sapiens (human) | Potency | 23.2637 | 1 | 8 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 22.2659 | 3 | 37 |
| pregnane X receptor | Rattus norvegicus (Norway rat) | Potency | 40.6723 | 1 | 5 |
| progesterone receptor | Homo sapiens (human) | Potency | 39.9237 | 3 | 25 |
| putative alpha-glucosidase | Oryza sativa Japonica Group (Japanese rice) | Potency | 28.1838 | 1 | 2 |
| pyruvate kinase | Leishmania mexicana mexicana | Potency | 15.8489 | 2 | 2 |
| pyruvate kinase PKM isoform a | Homo sapiens (human) | Potency | 39.8107 | 2 | 3 |
| Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 36.4261 | 1 | 2 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 19.3329 | 2 | 35 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 3.1481 | 1 | 3 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 13.3157 | 1 | 8 |
| relaxin receptor 1 isoform 1 | Homo sapiens (human) | Potency | 12.5893 | 1 | 1 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 22.8191 | 3 | 55 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 447.4457 | 4 | 46 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 26.7975 | 1 | 3 |
| signal transducer and activator of transcription 6, interleukin-4 induced | Homo sapiens (human) | Potency | 100.0000 | 1 | 1 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 20.6508 | 2 | 23 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 20.6508 | 2 | 23 |
| Smad3 | Homo sapiens (human) | Potency | 13.6404 | 1 | 10 |
| snurportin-1 | Homo sapiens (human) | Potency | 51.0004 | 2 | 3 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 26.7585 | 1 | 11 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 17.3610 | 1 | 11 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 18.9296 | 1 | 13 |
| TDP1 protein | Homo sapiens (human) | Potency | 17.8305 | 2 | 74 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 51.3695 | 1 | 4 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 24.9373 | 4 | 26 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 31.7585 | 3 | 49 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 12.4251 | 3 | 6 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 15.5396 | 5 | 38 |
| thyrotropin-releasing hormone receptor | Homo sapiens (human) | Potency | 25.2747 | 2 | 3 |
| transcriptional regulator ERG isoform 3 | Homo sapiens (human) | Potency | 21.4215 | 1 | 2 |
| transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) | Potency | 0.0433 | 3 | 3 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 5.4077 | 1 | 6 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 3.6053 | 1 | 5 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 3.6053 | 1 | 5 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 43.0898 | 2 | 20 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 25.6774 | 2 | 19 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 23.5475 | 5 | 26 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 31.0056 | 5 | 14 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 31.6884 | 1 | 14 |
| Vpr | Human immunodeficiency virus 1 | Potency | 5.8206 | 1 | 3 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase | Homo sapiens (human) | IC50 | 13.5000 | 1 | 1 |
| 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase | Homo sapiens (human) | Ki | 2.5600 | 1 | 1 |
| 3-phosphoinositide-dependent protein kinase 1 | Homo sapiens (human) | IC50 | 48.0000 | 2 | 2 |
| 4-aminobutyrate aminotransferase, mitochondrial | Rattus norvegicus (Norway rat) | IC50 | 1.7500 | 1 | 4 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | IC50 | 0.0405 | 2 | 3 |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | Ki | 5.0000 | 1 | 1 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | Ki | 0.0004 | 1 | 2 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | IC50 | 0.0007 | 1 | 2 |
| 5-hydroxytryptamine receptor 1B | Homo sapiens (human) | Ki | 0.0027 | 2 | 3 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | Ki | 0.0004 | 1 | 2 |
| 5-hydroxytryptamine receptor 1D | Homo sapiens (human) | Ki | 0.0032 | 4 | 5 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | IC50 | 0.0072 | 1 | 2 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | Ki | 0.0021 | 1 | 2 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | IC50 | 0.0051 | 1 | 2 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | Ki | 0.0033 | 1 | 2 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | IC50 | 0.0730 | 1 | 2 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | Ki | 0.0380 | 1 | 2 |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | IC50 | 0.0730 | 1 | 2 |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | Ki | 0.0380 | 1 | 2 |
| 5-hydroxytryptamine receptor 5A | Homo sapiens (human) | Ki | 0.0215 | 4 | 5 |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | IC50 | 0.0026 | 1 | 2 |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | Ki | 0.0012 | 1 | 2 |
| 5-hydroxytryptamine receptor 7 | Cavia porcellus (domestic guinea pig) | IC50 | 51.6000 | 1 | 2 |
| 5-lipoxygenase | Bos taurus (cattle) | IC50 | 35.0000 | 1 | 1 |
| Acetylcholinesterase | Homo sapiens (human) | IC50 | 217.5550 | 2 | 2 |
| Acid-sensing ion channel 1 | Rattus norvegicus (Norway rat) | IC50 | 344.3353 | 5 | 12 |
| Acid-sensing ion channel 3 | Rattus norvegicus (Norway rat) | IC50 | 366.9618 | 1 | 4 |
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | IC50 | 1,764.6250 | 2 | 4 |
| Adenosine receptor A2a | Rattus norvegicus (Norway rat) | IC50 | 2,348.3333 | 1 | 3 |
| Adenosine receptor A3 | Homo sapiens (human) | IC50 | 24.6220 | 1 | 1 |
| Adenosine receptor A3 | Homo sapiens (human) | Ki | 13.9170 | 1 | 1 |
| Adenylate cyclase | Arthrospira platensis | IC50 | 70.0000 | 1 | 1 |
| Albumin | Bos taurus (cattle) | IC50 | 3.0000 | 1 | 1 |
| Albumin | Homo sapiens (human) | Ki | 182,681,620,000.0000 | 1 | 5 |
| Aldo-keto reductase family 1 member B1 | Bos taurus (cattle) | IC50 | 0.2930 | 1 | 1 |
| Aldo-keto reductase family 1 member B1 | Homo sapiens (human) | IC50 | 60.9225 | 3 | 4 |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | IC50 | 4.0343 | 1 | 3 |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | Ki | 4.0010 | 1 | 3 |
| Aldo-keto reductase family 1 member B10 | Homo sapiens (human) | IC50 | 20.4220 | 4 | 5 |
| Aldo-keto reductase family 1 member C1 | Homo sapiens (human) | IC50 | 61.0560 | 2 | 5 |
| Aldo-keto reductase family 1 member C2 | Homo sapiens (human) | IC50 | 11.5540 | 7 | 10 |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | IC50 | 6.3894 | 10 | 14 |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | Ki | 1.0827 | 3 | 3 |
| Aldo-keto reductase family 1 member C4 | Homo sapiens (human) | IC50 | 100.0000 | 2 | 5 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 24.6220 | 1 | 1 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 6.9610 | 2 | 2 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 24.6220 | 1 | 1 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 6.9610 | 2 | 2 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | IC50 | 0.0390 | 1 | 2 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | Ki | 0.0127 | 2 | 3 |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.0050 | 1 | 1 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | IC50 | 0.0016 | 1 | 2 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | Ki | 0.0012 | 2 | 3 |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.0013 | 4 | 4 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | IC50 | 0.5079 | 1 | 3 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | Ki | 0.2318 | 1 | 3 |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.0000 | 1 | 1 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | IC50 | 0.0110 | 1 | 2 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | Ki | 0.0114 | 2 | 3 |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.0000 | 1 | 1 |
| Amine oxidase [flavin-containing] A | Homo sapiens (human) | IC50 | 0.9980 | 1 | 1 |
| Amyloid-beta precursor protein | Homo sapiens (human) | IC50 | 305.0000 | 1 | 1 |
| Androgen receptor | Homo sapiens (human) | IC50 | 31.3800 | 5 | 5 |
| Arachidonate 5-lipoxygenase-activating protein | Homo sapiens (human) | IC50 | 44.0000 | 1 | 1 |
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 14 |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | IC50 | 137.8556 | 9 | 9 |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | Ki | 249.0180 | 3 | 5 |
| ATP-dependent translocase ABCB1 | Mus musculus (house mouse) | Ki | 551.7000 | 2 | 4 |
| Beta lactamase (plasmid) | Pseudomonas aeruginosa | IC50 | 43.5450 | 1 | 1 |
| Beta-1 adrenergic receptor | Homo sapiens (human) | IC50 | 4.1420 | 1 | 1 |
| Beta-1 adrenergic receptor | Homo sapiens (human) | Ki | 2.3920 | 1 | 1 |
| Beta-2 adrenergic receptor | Homo sapiens (human) | IC50 | 2.7610 | 1 | 1 |
| Beta-2 adrenergic receptor | Homo sapiens (human) | Ki | 1.8980 | 1 | 1 |
| Beta-3 adrenergic receptor | Homo sapiens (human) | IC50 | 16.1240 | 1 | 1 |
| Beta-3 adrenergic receptor | Homo sapiens (human) | Ki | 12.0930 | 1 | 1 |
| Beta-carbonic anhydrase 1 | Mycobacterium tuberculosis H37Rv | Ki | 11.6600 | 3 | 6 |
| Bifunctional epoxide hydrolase 2 | Homo sapiens (human) | IC50 | 131.0700 | 2 | 2 |
| Bile salt export pump | Homo sapiens (human) | IC50 | 329.3767 | 5 | 49 |
| Bile salt export pump | Rattus norvegicus (Norway rat) | IC50 | 418.2833 | 1 | 6 |
| C-X-C chemokine receptor type 1 | Homo sapiens (human) | IC50 | 2.5405 | 3 | 4 |
| C-X-C chemokine receptor type 2 | Homo sapiens (human) | IC50 | 0.0750 | 1 | 2 |
| Calcium/calmodulin-dependent protein kinase type II subunit alpha | Rattus norvegicus (Norway rat) | Ki | 5.1000 | 1 | 1 |
| Calpain-2 catalytic subunit | Homo sapiens (human) | IC50 | 0.0020 | 1 | 1 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 11 |
| Cannabinoid receptor 1 | Homo sapiens (human) | IC50 | 0.0028 | 1 | 1 |
| Cannabinoid receptor 1 | Rattus norvegicus (Norway rat) | IC50 | 0.2180 | 1 | 1 |
| Cannabinoid receptor 1 | Homo sapiens (human) | Ki | 1.6423 | 21 | 22 |
| Cannabinoid receptor 1 | Mus musculus (house mouse) | Ki | 0.0405 | 2 | 2 |
| Cannabinoid receptor 1 | Rattus norvegicus (Norway rat) | Ki | 0.0468 | 10 | 10 |
| Cannabinoid receptor 2 | Rattus norvegicus (Norway rat) | IC50 | 0.2180 | 1 | 1 |
| Cannabinoid receptor 2 | Mus musculus (house mouse) | Ki | 0.0303 | 3 | 4 |
| Cannabinoid receptor 2 | Rattus norvegicus (Norway rat) | Ki | 0.0460 | 1 | 1 |
| Cannabinoid receptor 2 | Homo sapiens (human) | IC50 | 0.0095 | 1 | 1 |
| Cannabinoid receptor 2 | Homo sapiens (human) | Ki | 1.2322 | 24 | 25 |
| Carbonic anhydrase | Candida albicans SC5314 | Ki | 1.1135 | 3 | 8 |
| Carbonic anhydrase | Methanosarcina thermophila | Ki | 0.3800 | 2 | 4 |
| Carbonic anhydrase | Methanothermobacter thermautotrophicus str. Delta H | Ki | 49.7500 | 1 | 2 |
| Carbonic anhydrase | Saccharomyces cerevisiae S288C | Ki | 0.3810 | 1 | 2 |
| Carbonic anhydrase | Stylophora pistillata | Ki | 3.2000 | 1 | 2 |
| Carbonic anhydrase | Anopheles gambiae (African malaria mosquito) | Ki | 0.1685 | 1 | 2 |
| Carbonic anhydrase | Astrosclera willeyana | Ki | 0.6245 | 1 | 2 |
| Carbonic anhydrase | Cryptococcus neoformans var. grubii | Ki | 1.8800 | 1 | 2 |
| Carbonic anhydrase | Mycobacterium tuberculosis H37Rv | Ki | 7.7850 | 1 | 2 |
| Carbonic anhydrase | Nakaseomyces glabratus CBS 138 | Ki | 0.1065 | 1 | 2 |
| Carbonic anhydrase | Stylophora pistillata | Ki | 0.0314 | 2 | 4 |
| Carbonic anhydrase | Sulfurihydrogenibium sp. YO3AOP1 | Ki | 0.0061 | 1 | 2 |
| Carbonic anhydrase 1 | Homo sapiens (human) | IC50 | 211.8537 | 6 | 20 |
| Carbonic anhydrase 1 | Homo sapiens (human) | Ki | 142.6383 | 44 | 92 |
| Carbonic anhydrase 12 | Homo sapiens (human) | Ki | 76.7916 | 9 | 25 |
| Carbonic anhydrase 13 | Homo sapiens (human) | Ki | 0.2070 | 2 | 3 |
| Carbonic anhydrase 13 | Mus musculus (house mouse) | Ki | 139.0161 | 3 | 14 |
| Carbonic anhydrase 14 | Homo sapiens (human) | Ki | 120.4741 | 4 | 16 |
| Carbonic anhydrase 15 | Mus musculus (house mouse) | Ki | 1.2704 | 4 | 8 |
| Carbonic anhydrase 2 | Homo sapiens (human) | IC50 | 112.4226 | 7 | 22 |
| Carbonic anhydrase 2 | Homo sapiens (human) | Ki | 52.0308 | 54 | 109 |
| Carbonic anhydrase 2 | Mycobacterium tuberculosis H37Rv | Ki | 0.6975 | 2 | 4 |
| Carbonic anhydrase 3 | Homo sapiens (human) | Ki | 167.7778 | 5 | 18 |
| Carbonic anhydrase 4 | Bos taurus (cattle) | IC50 | 37.0636 | 3 | 15 |
| Carbonic anhydrase 4 | Bos taurus (cattle) | Ki | 0.3150 | 2 | 4 |
| Carbonic anhydrase 4 | Homo sapiens (human) | Ki | 92.0543 | 7 | 21 |
| Carbonic anhydrase 5A, mitochondrial | Homo sapiens (human) | Ki | 170.0000 | 4 | 16 |
| Carbonic anhydrase 5B, mitochondrial | Homo sapiens (human) | Ki | 138.2359 | 4 | 16 |
| Carbonic anhydrase 6 | Homo sapiens (human) | Ki | 117.0774 | 6 | 22 |
| Carbonic anhydrase 7 | Homo sapiens (human) | Ki | 84.9226 | 8 | 23 |
| Carbonic anhydrase 9 | Homo sapiens (human) | IC50 | 28.5860 | 3 | 7 |
| Carbonic anhydrase 9 | Homo sapiens (human) | Ki | 52.5270 | 18 | 40 |
| Carbonic anhydrase, alpha family | Hydrogenovibrio crunogenus XCL-2 | Ki | 0.7550 | 1 | 2 |
| caspase recruitment domain family, member 15 | Homo sapiens (human) | IC50 | 6.6330 | 1 | 1 |
| Caspase-1 | Homo sapiens (human) | IC50 | 17.7507 | 1 | 15 |
| Caspase-3 | Homo sapiens (human) | IC50 | 17.7507 | 1 | 15 |
| Caspase-4 | Homo sapiens (human) | IC50 | 17.7507 | 1 | 15 |
| Caspase-5 | Homo sapiens (human) | IC50 | 17.7507 | 1 | 15 |
| Caspase-9 | Homo sapiens (human) | IC50 | 17.7507 | 1 | 15 |
| Catechol O-methyltransferase | Mus musculus (house mouse) | IC50 | 4.5240 | 2 | 3 |
| Cereblon isoform 4 | Magnetospirillum gryphiswaldense | IC50 | 20.8000 | 1 | 1 |
| Cereblon isoform 4 | Magnetospirillum gryphiswaldense | Ki | 5,570.2333 | 3 | 3 |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | IC50 | 68.5000 | 2 | 2 |
| Chain A, Carbonic anhydrase II | Homo sapiens (human) | IC50 | 0.0210 | 1 | 1 |
| Chain A, Carbonic anhydrase II | Homo sapiens (human) | Ki | 0.0430 | 1 | 1 |
| Choline O-acetyltransferase | Rattus norvegicus (Norway rat) | Ki | 25,000.0000 | 1 | 1 |
| Cholinesterase | Homo sapiens (human) | IC50 | 600.0000 | 1 | 1 |
| Corticotropin-releasing factor receptor 2 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| Cruzipain | Trypanosoma cruzi | IC50 | 263.0000 | 2 | 2 |
| Cyclooxygenase-2 | Canis lupus familiaris (dog) | IC50 | 1.7733 | 2 | 3 |
| cysteine protease ATG4B isoform a | Homo sapiens (human) | IC50 | 8.1700 | 1 | 1 |
| Cytochrome c oxidase subunit 1 | Ovis aries (sheep) | IC50 | 38.5625 | 4 | 4 |
| Cytochrome c oxidase subunit 2 | Homo sapiens (human) | IC50 | 14.3554 | 6 | 8 |
| Cytochrome c oxidase subunit 2 | Ovis aries (sheep) | IC50 | 0.0882 | 4 | 4 |
| Cytochrome P450 1A2 | Homo sapiens (human) | IC50 | 2.0115 | 3 | 5 |
| Cytochrome P450 2C9 | Homo sapiens (human) | IC50 | 45.5556 | 2 | 9 |
| Cytochrome P450 2C9 | Homo sapiens (human) | Ki | 108,925,666,686.2833 | 4 | 6 |
| Cytochrome P450 2D1 | Rattus norvegicus (Norway rat) | IC50 | 46.5000 | 1 | 1 |
| Cytochrome P450 2D26 | Rattus norvegicus (Norway rat) | IC50 | 0.0940 | 1 | 1 |
| Cytochrome P450 2D3 | Rattus norvegicus (Norway rat) | IC50 | 12.0000 | 1 | 1 |
| Cytochrome P450 2D4 | Rattus norvegicus (Norway rat) | IC50 | 1.7000 | 1 | 1 |
| Cytochrome P450 2D6 | Homo sapiens (human) | IC50 | 2.2523 | 6 | 6 |
| Cytochrome P450 2D6 | Homo sapiens (human) | Ki | 15.0000 | 1 | 1 |
| Cytochrome P450 2E1 | Homo sapiens (human) | Ki | 9,500.0000 | 1 | 1 |
| Cytochrome P450 2J2 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 8 |
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 | 4.7498 | 3 | 4 |
| Cytochrome P450 3A4 | Homo sapiens (human) | Ki | 1,640.0000 | 1 | 3 |
| D(1A) dopamine receptor | Homo sapiens (human) | IC50 | 8.4368 | 2 | 4 |
| D(1A) dopamine receptor | Homo sapiens (human) | Ki | 3.2884 | 3 | 5 |
| D(1B) dopamine receptor | Homo sapiens (human) | Ki | 0.3050 | 1 | 1 |
| D(2) dopamine receptor | Homo sapiens (human) | IC50 | 0.1544 | 2 | 3 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 10.2150 | 2 | 2 |
| D(2) dopamine receptor | Homo sapiens (human) | Ki | 1.5323 | 3 | 4 |
| D(3) dopamine receptor | Homo sapiens (human) | IC50 | 0.0048 | 1 | 2 |
| D(3) dopamine receptor | Homo sapiens (human) | Ki | 0.4581 | 2 | 3 |
| D(4) dopamine receptor | Homo sapiens (human) | Ki | 1.0000 | 1 | 1 |
| Dehydrogenase/reductase SDR family member 9 | Rattus norvegicus (Norway rat) | IC50 | 100.0000 | 1 | 1 |
| Delta carbonic anhydrase | Conticribra weissflogii | Ki | 0.3215 | 1 | 2 |
| Delta-type opioid receptor | Mus musculus (house mouse) | Ki | 26.0160 | 2 | 4 |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | Ki | 0.0320 | 1 | 2 |
| Dihydrofolate reductase | Escherichia coli K-12 | IC50 | 348.9000 | 1 | 1 |
| Dihydrofolate reductase | Escherichia coli K-12 | Ki | 15.2400 | 1 | 1 |
| Dihydrofolate reductase | Homo sapiens (human) | Ki | 1,910.8000 | 1 | 5 |
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Homo sapiens (human) | IC50 | 10.5000 | 1 | 2 |
| Epidermal growth factor receptor | Homo sapiens (human) | IC50 | 10.0000 | 1 | 3 |
| Estrogen receptor 1 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 3 |
| Fatty acid-binding protein, intestinal | Homo sapiens (human) | Ki | 63.4000 | 2 | 7 |
| Fatty acid-binding protein, liver | Mus musculus (house mouse) | Ki | 1.0000 | 1 | 1 |
| Fatty acid-binding protein, liver | Rattus norvegicus (Norway rat) | Ki | 504.7670 | 2 | 10 |
| Fatty-acid amide hydrolase 1 | Homo sapiens (human) | IC50 | 43.6000 | 1 | 1 |
| Fatty-acid amide hydrolase 1 | Rattus norvegicus (Norway rat) | IC50 | 100.6667 | 2 | 3 |
| fMet-Leu-Phe receptor | Homo sapiens (human) | IC50 | 5.3000 | 1 | 1 |
| G-protein coupled receptor 55 | Homo sapiens (human) | IC50 | 14.2000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | IC50 | 16.7250 | 1 | 2 |
| glucose-6-phosphate 1-dehydrogenase isoform b | Homo sapiens (human) | IC50 | 80.0000 | 1 | 1 |
| glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase | Plasmodium berghei | IC50 | 63.1250 | 3 | 4 |
| Glutamate receptor ionotropic, NMDA 1 | Homo sapiens (human) | Ki | 10.5000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | IC50 | 160.5714 | 7 | 7 |
| Glutamate receptor ionotropic, NMDA 2A | Homo sapiens (human) | Ki | 10.5000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | IC50 | 160.5714 | 7 | 7 |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | IC50 | 180.6667 | 6 | 6 |
| Glutamate receptor ionotropic, NMDA 2B | Homo sapiens (human) | Ki | 10.5000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | IC50 | 180.6667 | 6 | 6 |
| Glutamate receptor ionotropic, NMDA 2C | Homo sapiens (human) | Ki | 10.5000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | IC50 | 180.6667 | 6 | 6 |
| Glutamate receptor ionotropic, NMDA 2D | Homo sapiens (human) | Ki | 10.5000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | IC50 | 180.6667 | 6 | 6 |
| Glutamate receptor ionotropic, NMDA 3A | Homo sapiens (human) | Ki | 10.5000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | IC50 | 180.6667 | 6 | 6 |
| Glutamate receptor ionotropic, NMDA 3B | Homo sapiens (human) | Ki | 10.5000 | 1 | 1 |
| Glutathione hydrolase 1 proenzyme | Homo sapiens (human) | IC50 | 36.0000 | 1 | 1 |
| Histidine-rich protein PFHRP-II | Plasmodium falciparum (malaria parasite P. falciparum) | IC50 | 7,400,000.0000 | 1 | 1 |
| Histone deacetylase 1 | Homo sapiens (human) | IC50 | 1.4110 | 2 | 2 |
| Histone deacetylase 11 | Homo sapiens (human) | IC50 | 1.6370 | 1 | 1 |
| Histone deacetylase 2 | Homo sapiens (human) | IC50 | 1.6370 | 1 | 1 |
| Histone deacetylase 3 | Homo sapiens (human) | IC50 | 1.6370 | 1 | 1 |
| Histone deacetylase 4 | Homo sapiens (human) | IC50 | 1.6370 | 1 | 1 |
| Histone deacetylase 5 | Homo sapiens (human) | IC50 | 1.6370 | 1 | 1 |
| Histone deacetylase 6 | Homo sapiens (human) | IC50 | 1.1400 | 2 | 2 |
| Histone deacetylase 7 | Homo sapiens (human) | IC50 | 1.6370 | 1 | 1 |
| Histone deacetylase 8 | Homo sapiens (human) | IC50 | 1.6370 | 1 | 1 |
| Histone deacetylase 9 | Homo sapiens (human) | IC50 | 1.6370 | 1 | 1 |
| Hormone-sensitive lipase | Rattus norvegicus (Norway rat) | IC50 | 1.2000 | 1 | 1 |
| Indoleamine 2,3-dioxygenase 1 | Mus musculus (house mouse) | IC50 | 0.0060 | 1 | 2 |
| Integrase | Human immunodeficiency virus 1 | IC50 | 100.0000 | 2 | 2 |
| Integrin alpha-IIb | Homo sapiens (human) | IC50 | 52.5000 | 2 | 2 |
| Integrin beta-3 | Homo sapiens (human) | IC50 | 52.5000 | 2 | 2 |
| Interleukin-8 | Homo sapiens (human) | IC50 | 0.5040 | 1 | 2 |
| L-lactate dehydrogenase A chain | Homo sapiens (human) | Ki | 14.0000 | 1 | 1 |
| L-lactate dehydrogenase B chain | Sus scrofa (pig) | Ki | 498.0000 | 1 | 1 |
| Lactoylglutathione lyase | Homo sapiens (human) | Ki | 206.4000 | 3 | 7 |
| leucine aminopeptidase | Homo sapiens (human) | IC50 | 0.3100 | 1 | 1 |
| Lysine-specific histone demethylase 1A | Homo sapiens (human) | IC50 | 0.6000 | 3 | 3 |
| Lysophosphatidylserine lipase ABHD12 | Homo sapiens (human) | IC50 | 11.6000 | 1 | 1 |
| M1-family alanyl aminopeptidase | Plasmodium falciparum 3D7 | IC50 | 47.5850 | 2 | 2 |
| M17 leucyl aminopeptidase | Plasmodium falciparum 3D7 | IC50 | 0.7050 | 2 | 2 |
| M18 aspartyl aminopeptidase | Plasmodium falciparum 3D7 | IC50 | 10.0200 | 1 | 1 |
| Matrix protein 2 | Influenza A virus (A/Puerto Rico/8/1934(H1N1)) | IC50 | 153.9250 | 4 | 4 |
| Matrix protein 2 | Influenza A virus (A/udorn/1972(H3N2)) | IC50 | 109.8600 | 5 | 5 |
| Metabotropic glutamate receptor 5 | Rattus norvegicus (Norway rat) | IC50 | 54.3000 | 1 | 1 |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | IC50 | 5.9270 | 1 | 1 |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | IC50 | 83.1050 | 2 | 2 |
| Monoacylglycerol lipase ABHD6 | Homo sapiens (human) | IC50 | 48.2000 | 1 | 1 |
| Monoglyceride lipase | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Mothers against decapentaplegic homolog 3 | Mus musculus (house mouse) | IC50 | 1.4300 | 1 | 1 |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | IC50 | 5.3000 | 1 | 2 |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | Ki | 0.0320 | 1 | 2 |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | Ki | 52.0000 | 1 | 2 |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | IC50 | 260.1500 | 1 | 4 |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | IC50 | 12.6000 | 1 | 1 |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 14 |
| Muscarinic acetylcholine receptor | Cavia porcellus (domestic guinea pig) | IC50 | 150.0000 | 1 | 1 |
| Muscarinic acetylcholine receptor | Cavia porcellus (domestic guinea pig) | Ki | 67.5911 | 4 | 4 |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | IC50 | 41.1368 | 4 | 4 |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | IC50 | 14.4639 | 7 | 13 |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | Ki | 135.4539 | 18 | 18 |
| Muscarinic acetylcholine receptor M1 | Mus musculus (house mouse) | Ki | 4.7822 | 5 | 5 |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Ki | 10.8368 | 12 | 16 |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | IC50 | 17.6728 | 7 | 7 |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | IC50 | 10.9373 | 8 | 11 |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | Ki | 1.2977 | 15 | 15 |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | Ki | 25.4284 | 10 | 13 |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | IC50 | 4.9900 | 2 | 2 |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | IC50 | 149.3980 | 8 | 10 |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | Ki | 30.1886 | 10 | 10 |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | Ki | 13.8161 | 28 | 31 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | IC50 | 2.0626 | 4 | 4 |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | IC50 | 12.6900 | 7 | 9 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | Ki | 6.8330 | 13 | 13 |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | Ki | 15.5317 | 8 | 11 |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | IC50 | 25.2000 | 1 | 1 |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | IC50 | 14.2475 | 6 | 8 |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | Ki | 37.6948 | 13 | 13 |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | Ki | 16.8249 | 7 | 10 |
| Myeloperoxidase | Homo sapiens (human) | IC50 | 200.0000 | 1 | 1 |
| Myoglobin | Homo sapiens (human) | IC50 | 2.3000 | 1 | 1 |
| NAD(+) hydrolase SARM1 | Homo sapiens (human) | IC50 | 145.0000 | 1 | 1 |
| NAD(+) hydrolase SARM1 | Homo sapiens (human) | Ki | 70.0000 | 1 | 1 |
| NADH-ubiquinone oxidoreductase chain 1 | Bos taurus (cattle) | IC50 | 52.4808 | 1 | 1 |
| Neuronal acetylcholine receptor subunit alpha-10 | Rattus norvegicus (Norway rat) | Ki | 0.4500 | 1 | 2 |
| Neuronal acetylcholine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Ki | 0.3700 | 2 | 3 |
| Neuronal acetylcholine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Ki | 1.7000 | 3 | 4 |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | IC50 | 26.6100 | 1 | 1 |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Ki | 0.6975 | 3 | 4 |
| Neuronal acetylcholine receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Ki | 0.4500 | 1 | 2 |
| Neuronal acetylcholine receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Ki | 0.4500 | 1 | 2 |
| Neuronal acetylcholine receptor subunit alpha-7 | Rattus norvegicus (Norway rat) | Ki | 0.4500 | 1 | 2 |
| Neuronal acetylcholine receptor subunit alpha-9 | Rattus norvegicus (Norway rat) | Ki | 0.4500 | 1 | 2 |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | IC50 | 26.6100 | 1 | 1 |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Ki | 0.5600 | 4 | 5 |
| Neuronal acetylcholine receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Ki | 0.4500 | 1 | 2 |
| Neuronal acetylcholine receptor subunit beta-4 | Rattus norvegicus (Norway rat) | Ki | 1.7500 | 3 | 4 |
| Nicotinate phosphoribosyltransferase | Homo sapiens (human) | Ki | 0.0005 | 1 | 6 |
| Nitric oxide synthase, inducible | Mus musculus (house mouse) | IC50 | 50.0000 | 1 | 1 |
| Nuclear receptor subfamily 4 group A member 2 | Homo sapiens (human) | IC50 | 13.4000 | 1 | 1 |
| P2X purinoceptor 4 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| P2Y purinoceptor 12 | Rattus norvegicus (Norway rat) | IC50 | 0.0300 | 1 | 2 |
| phospholipase A2 precursor | Homo sapiens (human) | IC50 | 7.7400 | 1 | 1 |
| Pleiotropic ABC efflux transporter of multiple drugs | Saccharomyces cerevisiae S288C | IC50 | 9.6000 | 1 | 1 |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | IC50 | 1.6370 | 1 | 1 |
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | IC50 | 21.5300 | 3 | 3 |
| Polyunsaturated fatty acid 5-lipoxygenase | Rattus norvegicus (Norway rat) | IC50 | 24.5627 | 9 | 14 |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | IC50 | 28.3800 | 1 | 1 |
| Potassium channel subfamily K member 2 | Homo sapiens (human) | IC50 | 3.8500 | 1 | 1 |
| Potassium voltage-gated channel subfamily A member 1 | Homo sapiens (human) | IC50 | 29.0000 | 1 | 1 |
| Potassium voltage-gated channel subfamily E member 1 | Homo sapiens (human) | IC50 | 158.4890 | 1 | 1 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | IC50 | 246.8570 | 5 | 5 |
| Potassium voltage-gated channel subfamily KQT member 1 | Homo sapiens (human) | IC50 | 158.4890 | 1 | 1 |
| Procathepsin L | Homo sapiens (human) | IC50 | 0.5600 | 1 | 1 |
| Prostaglandin E synthase | Homo sapiens (human) | IC50 | 26.9883 | 3 | 3 |
| Prostaglandin G/H synthase 1 | Canis lupus familiaris (dog) | IC50 | 14.2850 | 1 | 2 |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | IC50 | 43.0061 | 109 | 153 |
| Prostaglandin G/H synthase 1 | Mus musculus (house mouse) | IC50 | 3.2601 | 9 | 9 |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | IC50 | 279.2450 | 185 | 283 |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | Ki | 62.0000 | 1 | 1 |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | Ki | 5.0000 | 2 | 2 |
| Prostaglandin G/H synthase 1 | Bos taurus (cattle) | IC50 | 712.5532 | 9 | 20 |
| Prostaglandin G/H synthase 1 | Rattus norvegicus (Norway rat) | IC50 | 12.9421 | 12 | 14 |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | IC50 | 88.0569 | 225 | 312 |
| Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | IC50 | 7.4303 | 26 | 28 |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | IC50 | 122.3907 | 84 | 121 |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | Ki | 17.3336 | 2 | 3 |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | Ki | 4.7450 | 2 | 2 |
| Prostaglandin G/H synthase 2 | Bos taurus (cattle) | IC50 | 500.2595 | 3 | 6 |
| Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | IC50 | 9.8515 | 12 | 14 |
| Prostaglandin-H2 D-isomerase | Mus musculus (house mouse) | IC50 | 750.1000 | 1 | 2 |
| Protein cereblon | Homo sapiens (human) | IC50 | 264.0000 | 1 | 1 |
| Protein cereblon | Homo sapiens (human) | Ki | 68,568.5000 | 2 | 2 |
| Pyruvate kinase PKM | Homo sapiens (human) | IC50 | 21.0000 | 1 | 1 |
| Quinolone resistance protein NorA | Staphylococcus aureus | IC50 | 40.0000 | 1 | 1 |
| receptor-interacting serine/threonine-protein kinase 2 isoform 1 | Homo sapiens (human) | IC50 | 6.6330 | 1 | 1 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | IC50 | 28.0000 | 1 | 1 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | Ki | 107.3600 | 1 | 1 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | Ki | 107.3600 | 1 | 1 |
| Retinoic acid receptor RXR-alpha | Homo sapiens (human) | IC50 | 82.9000 | 1 | 1 |
| Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | IC50 | 6,700.0000 | 1 | 1 |
| Rho-associated protein kinase 2 | Rattus norvegicus (Norway rat) | IC50 | 100.0000 | 1 | 2 |
| Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | IC50 | 8.9800 | 1 | 4 |
| Serum paraoxonase/arylesterase 1 | Homo sapiens (human) | Ki | 157.5000 | 1 | 2 |
| Sigma intracellular receptor 2 | Rattus norvegicus (Norway rat) | IC50 | 0.0500 | 1 | 1 |
| Sigma non-opioid intracellular receptor 1 | Rattus norvegicus (Norway rat) | IC50 | 10.0000 | 1 | 1 |
| Snake venom metalloproteinase BaP1 | Bothrops asper (terciopelo) | IC50 | 54.3000 | 1 | 1 |
| Sodium channel protein type 1 subunit alpha | Rattus norvegicus (Norway rat) | IC50 | 116.3800 | 2 | 5 |
| Sodium channel protein type 10 subunit alpha | Homo sapiens (human) | IC50 | 97.0000 | 2 | 2 |
| Sodium channel protein type 2 subunit alpha | Homo sapiens (human) | IC50 | 42.3333 | 3 | 3 |
| Sodium channel protein type 2 subunit alpha | Rattus norvegicus (Norway rat) | IC50 | 93.1286 | 4 | 7 |
| Sodium channel protein type 3 subunit alpha | Homo sapiens (human) | IC50 | 17.0000 | 1 | 1 |
| Sodium channel protein type 3 subunit alpha | Rattus norvegicus (Norway rat) | IC50 | 116.3800 | 2 | 5 |
| Sodium channel protein type 4 subunit alpha | Homo sapiens (human) | Ki | 34.5000 | 1 | 2 |
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | IC50 | 67.2702 | 3 | 3 |
| Sodium channel protein type 9 subunit alpha | Homo sapiens (human) | IC50 | 19.5000 | 2 | 2 |
| Sodium channel protein type 9 subunit alpha | Homo sapiens (human) | Ki | 32.7000 | 1 | 1 |
| Sodium- and chloride-dependent betaine transporter | Rattus norvegicus (Norway rat) | IC50 | 0.5000 | 1 | 1 |
| Sodium- and chloride-dependent GABA transporter 1 | Rattus norvegicus (Norway rat) | IC50 | 0.5000 | 1 | 1 |
| Sodium- and chloride-dependent GABA transporter 2 | Rattus norvegicus (Norway rat) | IC50 | 0.5000 | 1 | 1 |
| Sodium- and chloride-dependent GABA transporter 3 | Rattus norvegicus (Norway rat) | IC50 | 0.5000 | 1 | 1 |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | Ki | 0.0400 | 1 | 1 |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | IC50 | 2.4310 | 1 | 1 |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | Ki | 1.9310 | 1 | 1 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | IC50 | 4.0343 | 1 | 3 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | Ki | 4.0010 | 1 | 3 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | IC50 | 6.2760 | 1 | 1 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | Ki | 3.3340 | 1 | 1 |
| Sodium/hydrogen exchanger 1 | Rattus norvegicus (Norway rat) | IC50 | 33.1000 | 1 | 1 |
| Solute carrier family 22 member 1 | Mus musculus (house mouse) | IC50 | 0.2800 | 1 | 1 |
| Solute carrier family 22 member 1 | Rattus norvegicus (Norway rat) | IC50 | 143.7333 | 4 | 6 |
| Solute carrier family 22 member 1 | Rattus norvegicus (Norway rat) | Ki | 2.6150 | 2 | 2 |
| Solute carrier family 22 member 1 | Homo sapiens (human) | IC50 | 51.6000 | 1 | 1 |
| Solute carrier family 22 member 1 | Homo sapiens (human) | Ki | 22.9000 | 1 | 1 |
| Solute carrier family 22 member 2 | Homo sapiens (human) | IC50 | 36.4500 | 2 | 2 |
| Solute carrier family 22 member 2 | Mus musculus (house mouse) | IC50 | 2.8000 | 1 | 1 |
| Solute carrier family 22 member 2 | Rattus norvegicus (Norway rat) | IC50 | 164.3800 | 3 | 5 |
| Solute carrier family 22 member 2 | Homo sapiens (human) | Ki | 3.4000 | 1 | 1 |
| Solute carrier family 22 member 2 | Rattus norvegicus (Norway rat) | Ki | 55.0000 | 1 | 1 |
| Solute carrier family 22 member 20 | Mus musculus (house mouse) | Ki | 51.3878 | 1 | 4 |
| Solute carrier family 22 member 6 | Homo sapiens (human) | IC50 | 38.5929 | 1 | 7 |
| Solute carrier family 22 member 6 | Mus musculus (house mouse) | Ki | 347.0521 | 1 | 4 |
| Solute carrier family 22 member 6 | Rattus norvegicus (Norway rat) | Ki | 450.3571 | 2 | 7 |
| Solute carrier family 22 member 8 | Homo sapiens (human) | Ki | 602.3500 | 1 | 2 |
| Solute carrier organic anion transporter family member 1A1 | Rattus norvegicus (Norway rat) | Ki | 101.3500 | 1 | 2 |
| Solute carrier organic anion transporter family member 1A4 | Rattus norvegicus (Norway rat) | Ki | 1,216.9050 | 1 | 2 |
| Substance-P receptor | Cavia porcellus (domestic guinea pig) | IC50 | 1.7500 | 1 | 2 |
| Thromboxane-A synthase | Homo sapiens (human) | IC50 | 3.0640 | 1 | 1 |
| Tissue factor | Homo sapiens (human) | IC50 | 0.0228 | 1 | 1 |
| Toll-like receptor 4 | Homo sapiens (human) | IC50 | 1.4000 | 1 | 1 |
| Transcription factor SOX-18 | Mus musculus (house mouse) | IC50 | 220.0000 | 2 | 2 |
| Transcriptional enhancer factor TEF-3 | Homo sapiens (human) | IC50 | 54.0000 | 1 | 1 |
| Transforming growth factor beta-1 proprotein | Mus musculus (house mouse) | IC50 | 1.4300 | 1 | 1 |
| Transient receptor potential cation channel subfamily M member 2 | Homo sapiens (human) | IC50 | 70.0000 | 2 | 2 |
| Transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) | IC50 | 0.0080 | 2 | 2 |
| Transient receptor potential cation channel subfamily V member 1 | Rattus norvegicus (Norway rat) | IC50 | 0.0190 | 1 | 1 |
| Transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) | Ki | 1.1865 | 4 | 4 |
| Transient receptor potential cation channel subfamily V member 1 | Rattus norvegicus (Norway rat) | Ki | 1.7795 | 4 | 4 |
| Transthyretin | Homo sapiens (human) | IC50 | 6.2600 | 5 | 5 |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | IC50 | 3.1600 | 1 | 1 |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | IC50 | 6.4990 | 1 | 1 |
| UDP-glucuronosyltransferase 1-6 | Homo sapiens (human) | IC50 | 249.3000 | 1 | 10 |
| UDP-glucuronosyltransferase 1-6 | Homo sapiens (human) | Ki | 23.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | IC50 | 249.3000 | 1 | 10 |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | Ki | 52.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 1A10 | Homo sapiens (human) | Ki | 28.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 1A4 | Homo sapiens (human) | IC50 | 249.3000 | 1 | 10 |
| UDP-glucuronosyltransferase 1A7 | Homo sapiens (human) | Ki | 19.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 1A9 | Homo sapiens (human) | Ki | 11.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 2B10 | Homo sapiens (human) | IC50 | 249.3000 | 1 | 10 |
| UDP-glucuronosyltransferase 2B7 | Homo sapiens (human) | IC50 | 249.3000 | 1 | 10 |
| Urotensin-2 receptor | Rattus norvegicus (Norway rat) | IC50 | 3.9500 | 1 | 4 |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | IC50 | 1,421.9100 | 2 | 2 |
| Voltage-dependent T-type calcium channel subunit alpha-1G | Homo sapiens (human) | IC50 | 0.0370 | 2 | 2 |
| Voltage-dependent T-type calcium channel subunit alpha-1H | Homo sapiens (human) | IC50 | 0.0730 | 2 | 2 |
| Voltage-dependent T-type calcium channel subunit alpha-1I | Homo sapiens (human) | IC50 | 0.0860 | 2 | 2 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | EC50 | 5.3360 | 1 | 1 |
| Acid-sensing ion channel 5 | Rattus norvegicus (Norway rat) | EC50 | 2,600.0000 | 1 | 1 |
| Albumin | Homo sapiens (human) | Kd | 77.7430 | 3 | 5 |
| Albumin | Rattus norvegicus (Norway rat) | Kd | 52.2350 | 1 | 2 |
| Alpha-1A adrenergic receptor | Bos taurus (cattle) | EC50 | 0.3760 | 1 | 1 |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | Kd | 0.0282 | 1 | 1 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | Kd | 0.2089 | 1 | 1 |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | Kd | 0.0282 | 1 | 1 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | Kd | 0.2089 | 1 | 1 |
| Alpha-1B adrenergic receptor | Cricetulus griseus (Chinese hamster) | EC50 | 0.3640 | 1 | 1 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | Kd | 0.0282 | 1 | 1 |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | Kd | 0.2089 | 1 | 1 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | EC50 | 0.0015 | 3 | 3 |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | Kd | 0.0562 | 1 | 1 |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | Kd | 0.0562 | 1 | 1 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | EC50 | 0.0005 | 1 | 1 |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | Kd | 0.0562 | 1 | 1 |
| Androgen receptor | Homo sapiens (human) | EC50 | 67.0000 | 1 | 1 |
| Angiotensin-converting enzyme 2 | Homo sapiens (human) | EC50 | 2.5000 | 1 | 1 |
| Cannabinoid receptor 1 | Homo sapiens (human) | EC50 | 0.0458 | 3 | 3 |
| Cannabinoid receptor 1 | Rattus norvegicus (Norway rat) | EC50 | 0.0738 | 2 | 3 |
| Cannabinoid receptor 2 | Mus musculus (house mouse) | EC50 | 0.0073 | 1 | 1 |
| Cannabinoid receptor 2 | Homo sapiens (human) | EC50 | 0.0086 | 3 | 3 |
| cell division cycle 42 (GTP binding protein, 25kDa), partial | Homo sapiens (human) | EC50 | 24.3552 | 4 | 10 |
| Chain A, Phospholipase A2 isoform 3 | Naja sagittifera | Kd | 6.4000 | 1 | 1 |
| Chain A, PROTEIN (TRANSTHYRETIN) | Homo sapiens (human) | Kd | 0.0300 | 1 | 1 |
| Chain B, PROTEIN (TRANSTHYRETIN) | Homo sapiens (human) | Kd | 0.0300 | 1 | 1 |
| Complement C5 | Homo sapiens (human) | Kd | 0.5700 | 1 | 1 |
| Cytochrome P450 1A1 | Homo sapiens (human) | Kd | 19.1000 | 1 | 1 |
| Cytochrome P450 2B6 | Homo sapiens (human) | EC50 | 145.0000 | 1 | 1 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | EC50 | 0.3000 | 1 | 1 |
| D(3) dopamine receptor | Homo sapiens (human) | EC50 | 0.0102 | 1 | 1 |
| electroneutral potassium-chloride cotransporter KCC2 | Homo sapiens (human) | EC50 | 3.2500 | 1 | 1 |
| Estrogen receptor | Mus musculus (house mouse) | EC50 | 1.5180 | 1 | 2 |
| Estrogen receptor beta | Mus musculus (house mouse) | EC50 | 1.5180 | 1 | 2 |
| Frizzled-8 | Mus musculus (house mouse) | Kd | 16.8000 | 1 | 1 |
| G-protein coupled bile acid receptor 1 | Homo sapiens (human) | EC50 | 10.0000 | 1 | 1 |
| G-protein coupled receptor 55 | Homo sapiens (human) | EC50 | 10.0000 | 1 | 1 |
| Glutamate receptor 1 | Rattus norvegicus (Norway rat) | EC50 | 0.1995 | 1 | 1 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | EC50 | 0.1995 | 1 | 1 |
| Glutamate receptor 3 | Rattus norvegicus (Norway rat) | EC50 | 0.1995 | 1 | 1 |
| Glutamate receptor 4 | Rattus norvegicus (Norway rat) | EC50 | 0.1995 | 1 | 1 |
| Glycine receptor subunit alpha-1 | Homo sapiens (human) | EC50 | 0.8400 | 1 | 2 |
| glycogen synthase kinase-3 beta isoform 1 | Homo sapiens (human) | EC50 | 300.0000 | 1 | 1 |
| GTP-binding protein (rab7) | Canis lupus familiaris (dog) | EC50 | 24.9550 | 2 | 5 |
| High mobility group protein B1 | Homo sapiens (human) | Kd | 1,600.0000 | 1 | 1 |
| Histone deacetylase 1 | Homo sapiens (human) | Kd | 1,000.0000 | 1 | 1 |
| Histone deacetylase 2 | Homo sapiens (human) | Kd | 1,000.0000 | 1 | 1 |
| Histone deacetylase 3 | Homo sapiens (human) | Kd | 341.0000 | 1 | 1 |
| Histone deacetylase 6 | Homo sapiens (human) | Kd | 10.7000 | 1 | 1 |
| Histone deacetylase 8 | Homo sapiens (human) | EC50 | 16.9000 | 1 | 1 |
| Histone deacetylase 8 | Homo sapiens (human) | Kd | 235.0000 | 1 | 1 |
| Hsf1 protein | Mus musculus (house mouse) | EC50 | 195.0000 | 1 | 1 |
| Insulin-like growth factor-binding protein 5 | Homo sapiens (human) | Kd | 696,000.0000 | 7 | 7 |
| L-lactate dehydrogenase B chain | Sus scrofa (pig) | EC50 | 78.0000 | 1 | 1 |
| Leukotriene B4 receptor 1 | Homo sapiens (human) | EC50 | 0.0700 | 1 | 1 |
| Leukotriene B4 receptor 2 | Homo sapiens (human) | EC50 | 0.0700 | 1 | 1 |
| Major prion protein | Homo sapiens (human) | EC50 | 10.0000 | 1 | 1 |
| Matrix protein 2 | Influenza A virus (A/udorn/1972(H3N2)) | EC50 | 0.6600 | 2 | 2 |
| Matrix protein 2 | Influenza A virus (A/Puerto Rico/8/1934(H1N1)) | Kd | 0.3200 | 1 | 1 |
| Matrix protein 2 | Influenza A virus (A/udorn/1972(H3N2)) | Kd | 58.2925 | 4 | 4 |
| mu-type opioid receptor isoform MOR-1 | Homo sapiens (human) | EC50 | 92.5900 | 1 | 1 |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | EC50 | 1,108,477,796.2420 | 18 | 18 |
| Muscarinic acetylcholine receptor M1 | Mus musculus (house mouse) | EC50 | 40.0000 | 1 | 1 |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | EC50 | 0.6500 | 1 | 1 |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | Kd | 17.0000 | 1 | 2 |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | EC50 | 1,936,025,008.0114 | 8 | 8 |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | Kd | 17.0000 | 1 | 2 |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | EC50 | 5,568,744,447.3554 | 9 | 9 |
| Muscarinic acetylcholine receptor M3 | Mus musculus (house mouse) | EC50 | 9.9000 | 1 | 1 |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | EC50 | 0.7027 | 21 | 21 |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | Kd | 17.0000 | 1 | 2 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | EC50 | 9.6071 | 7 | 7 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | Kd | 17.0000 | 1 | 2 |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | EC50 | 9,120,110,011.0422 | 10 | 10 |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | Kd | 17.0000 | 1 | 2 |
| N-arachidonyl glycine receptor | Homo sapiens (human) | EC50 | 4.6100 | 1 | 1 |
| nuclear factor NF-kappa-B p105 subunit isoform 1 | Homo sapiens (human) | EC50 | 1.5180 | 1 | 1 |
| Nuclear receptor subfamily 1 group I member 2 | Homo sapiens (human) | EC50 | 18.9333 | 3 | 3 |
| ORF73 | Human gammaherpesvirus 8 | EC50 | 75.0000 | 1 | 1 |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | EC50 | 22.6500 | 1 | 1 |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | Kd | 100.0000 | 1 | 1 |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | Kd | 12.3000 | 1 | 1 |
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | EC50 | 0.0700 | 1 | 1 |
| Potassium channel subfamily K member 18 | Homo sapiens (human) | EC50 | 287.0000 | 2 | 2 |
| Potassium channel subfamily K member 2 | Homo sapiens (human) | EC50 | 100.0000 | 1 | 1 |
| Procathepsin L | Homo sapiens (human) | EC50 | 2.5000 | 1 | 1 |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | Kd | 0.7891 | 1 | 1 |
| Rac1 protein | Homo sapiens (human) | EC50 | 31.1866 | 4 | 11 |
| ras protein, partial | Homo sapiens (human) | EC50 | 30.0000 | 4 | 11 |
| Ras-related protein Rab-2A | Canis lupus familiaris (dog) | EC50 | 30.0000 | 2 | 5 |
| Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | EC50 | 2.5000 | 1 | 1 |
| Replicase polyprotein 1ab | Betacoronavirus England 1 | EC50 | 2.5000 | 1 | 1 |
| Replicase polyprotein 1ab | Human coronavirus 229E | EC50 | 2.5000 | 1 | 1 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | EC50 | 2.5000 | 1 | 1 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | EC50 | 2.5000 | 1 | 1 |
| Sigma non-opioid intracellular receptor 1 | Cavia porcellus (domestic guinea pig) | EC50 | 19,952,600,000.0000 | 1 | 1 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | EC50 | 30.0000 | 1 | 8 |
| Sigma non-opioid intracellular receptor 1 | Rattus norvegicus (Norway rat) | EC50 | 30.0000 | 2 | 7 |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | EC50 | 30.0000 | 1 | 2 |
| Spike glycoprotein | Betacoronavirus England 1 | EC50 | 2.5000 | 1 | 1 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | EC50 | 2.5000 | 1 | 1 |
| Stromelysin-1 | Homo sapiens (human) | Kd | 25,000.0000 | 1 | 1 |
| SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2, isoform CRA_a | Homo sapiens (human) | EC50 | 91.1610 | 1 | 1 |
| Taste receptor type 2 member 16 | Homo sapiens (human) | EC50 | 1,400.0000 | 2 | 2 |
| transcription factor p65 isoform 1 | Homo sapiens (human) | EC50 | 1.5180 | 1 | 1 |
| Transcriptional enhancer factor TEF-3 | Homo sapiens (human) | Kd | 76.6667 | 3 | 3 |
| Transient receptor potential cation channel subfamily A member 1 | Homo sapiens (human) | EC50 | 61.1690 | 2 | 6 |
| Transient receptor potential cation channel subfamily A member 1 | Rattus norvegicus (Norway rat) | EC50 | 0.2300 | 1 | 1 |
| Transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) | EC50 | 1.8463 | 17 | 18 |
| Transient receptor potential cation channel subfamily V member 1 | Rattus norvegicus (Norway rat) | EC50 | 0.4094 | 8 | 9 |
| Transient receptor potential cation channel subfamily V member 2 | Rattus norvegicus (Norway rat) | EC50 | 0.2460 | 4 | 5 |
| Transient receptor potential cation channel subfamily V member 4 | Rattus norvegicus (Norway rat) | EC50 | 0.2460 | 4 | 5 |
| Transmembrane protease serine 2 | Homo sapiens (human) | EC50 | 2.5000 | 1 | 1 |
| Transthyretin | Homo sapiens (human) | EC50 | 5.6000 | 1 | 1 |
| Transthyretin | Homo sapiens (human) | Kd | 1.1911 | 6 | 11 |